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Abstract
 
Regulatory T cells have been clearly implicated in the control of disease in murine models of
autoimmunity. The paucity of data regarding the role of these lymphocytes in human autoimmune
disease has prompted us to examine their function in patients with rheumatoid arthritis (RA).
Regulatory (CD4
 
 
 
CD25
 
 
 
) T cells isolated from patients with active RA displayed an anergic
phenotype upon stimulation with anti-CD3 and anti-CD28 antibodies, and suppressed the
proliferation of effector T cells in vitro. However, they were unable to suppress proinflammatory
cytokine secretion from activated T cells and monocytes, or to convey a suppressive phenotype
to effector CD4
 
 
 
CD25
 
 
 
 T cells. Treatment with antitumor necrosis factor 
 
 
 
 (TNF
 
 
 
; Inflix-
imab) restored the capacity of regulatory T cells to inhibit cytokine production and to convey a
suppressive phenotype to “conventional” T cells. Furthermore, anti-TNF
 
 
 
 treatment led to a
significant rise in the number of peripheral blood regulatory T cells in RA patients responding
to this treatment, which correlated with a reduction in C reactive protein. These data are the
first to demonstrate that regulatory T cells are functionally compromised in RA, and indicate
that modulation of regulatory T cells by anti-TNF
 
 
 
 therapy may be a further mechanism by
which this disease is ameliorated.
Key words: T lymphocytes • tolerane • autoimmune disease • TNF
 
 
 
 • cytokines
 
Introduction
 
Studies in rodents have provided firm evidence for the exist-
ence of a naturally occurring population of CD4
 
 
 
CD25
 
 
 
professional regulatory/suppressor T cells, which, upon in
vitro TCR-mediated stimulation, suppress the proliferation
of effector T cells (1, 2). These cells appear central to the
control of T cell homeostasis and in the modulation of
immune responses to autoantigens, cancer cells, pathogens,
and alloantigens (1, 2). In the periphery of young mice not
prone to autoimmune diseases, regulatory T cells constitute
a stable 10% of CD4
 
 
 
 T cells. This proportion appears to
be reduced in mice genetically prone to autoimmune disease
such as diabetes (3, 4). Transfer of regulatory T cells is able
to prevent a wide range of experimental autoimmune diseases,
including diabetes, experimental autoimmune encephalo-
myelitis, and colitis (3–6). In addition, depletion of regulatory
T cells has been shown to exacerbate various experimental
autoimmune diseases, including collagen induced arthritis
(7). In humans, an analogous population of CD4
 
 
 
CD25
 
 
 
regulatory T cells has been identified in the peripheral
blood (PB; 8–11) and in the thymus (12, 13). In comparison
to the wealth of evidence from animal models, much less is
known about human regulatory T cells and their potential
to suppress autoimmune disease in patients. One recent
analysis of human regulatory T cells demonstrated a reduc-
tion in their numbers in the PB of newly diagnosed type-1
diabetic patients, suggesting that a deficiency in this subset
could be responsible for the breakdown of tolerance in
human diabetes (14).
Rheumatoid arthritis (RA) is a chronic inflammatory
disorder that ultimately leads to the destruction of joint archi-
tecture. The pathogenic events that lead to the development
of RA are not fully understood, although the pivotal role
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that proinflammatory cytokines (i.e., such as TNF
 
 
 
, IL-1
 
 
 
,
IL-6, etc.) play in the induction and maintenance of this
disease is well documented (15). Moreover, these cytokines
are important in the homeostasis of T lymphocytes (16),
including regulation of the CD4
 
 
 
CD25
 
 
 
 regulatory T cell
subset. In RA, the CD4
 
 
 
CD25
 
 
 
 regulatory T cell subset
represents 
 
 
 
5–10% of the CD4
 
 
 
 T cell population, and
this population has been shown to suppress the in vitro
proliferation of autologous CD4
 
 
 
 T cells (17). Because
proinflammatory cytokines are critical to the pathogenesis
of RA, we postulated that regulatory T cells in active RA,
although still capable of suppressing T cell proliferation,
may be defective in controlling proinflammatory cyto-
kine production. Therefore, we set out to investigate any
changes in the function and/or number of regulatory T
cells in the PB of patients with active RA and to determine
if clinical response to anti-TNF
 
 
 
 therapy results in changes
in this cell population.
In this paper, we present evidence to suggest that regula-
tory T cells derived from patients with active RA are de-
fective in their ability to suppress cytokine production and
in their ability to convey a suppressive phenotype to CD4
 
 
 
effector T cells. We go on to demonstrate that clinical re-
sponse to anti-TNF
 
 
 
, but not conventional therapies, in
RA patients is correlated with an increased number of PB
regulatory T cells, suggesting a possible additional mecha-
nism by which blockade of TNF
 
 
 
 results in amelioration
of RA.
 
Materials and Methods
 
Study Population. 
 
27 patients with active RA, fulfilling the
revised classification criteria of the American College of Rheu-
matology for RA, were evaluated before and after anti-TNF
 
 
 
therapy (Infliximab was given at a dose of 3 mg/kg i.v. at weeks
0, 2, 6, and at every 8 wk in combination with stable doses of
methotrexate 7.5–15 mg/wk orally) and stable nonsteroidal anti-
inflammatory drugs. Patients taking prednisolone were excluded
from the study because steroids are known to affect lymphocyte
function and CD25 expression (18). Only patients with a disease
activity score of 
 
 
 
5.1 were treated with anti-TNF
 
 
 
 therapy. Re-
sponse was defined as a drop in the disease activity score of 
 
 
 
1.2.
Patients responding to conventional dosages of methotrexate (15-
25 mg/wk) were also included in this analysis.
 
Antibodies. 
 
The following Abs were used: FITC-conju-
gated anti-CD4 (RPAT4), Cy-Chrome–conjugated anti-CD25
(M-A251), and PE-conjugated anti-CD3 (UCHT1). Staining of
MACS
 
®
 
-sorted T cells included the following: PE-conjugated,
FITC-conjugated anti-CD3 (UCHT1); anti-CD4 (RPAT4); anti-
CD25 (4E3); anti-CD28 (CD28.2); and anti–CTLA-4 (BNI3; all
obtained from BD Biosciences). For T cell activation the stimula-
tory Abs, anti-CD3 (OKT3) and anti-CD28 (CD28.2; obtained
from BD Biosciences) were used as indicated.
 
Cell Isolation. 
 
PBMCs were isolated by Ficoll-Paque Plus
(Amersham Biosciences) gradient centrifugation. Cells were cul-
tured in RPMI 1640 media supplemented with 2 nM 
 
l
 
-gluta-
mine, 5 mM Hepes, 100 U/
 
 
 
g/ml penicillin/streptomycin, 0.5
mM sodium pyruvate, 0.05 mM of nonessential amino acids
(both obtained from Life Technologies), and 10% FCS (all ob-
tained from BioWhittaker) in 96-well U-bottom plates (Nunc).
Non-CD4
 
 
 
 T cells were stained using a biotin antibody cocktail
(10 
 
 
 
l/10
 
7
 
 total cells), incubated for 10 min at 4
 
 
 
C, magnetically
labeled with antibiotin microbeads (20 
 
 
 
l/10
 
7
 
 total cells), incu-
bated for 15 min at 4
 
 
 
C, washed twice, and depleted over a
MACS
 
®
 
 LD column. CD4
 
 
 
CD25
 
 
 
 T cells were directly labeled
with anti-CD25 microbeads (10 
 
 
 
l/10
 
7
 
 CD4
 
 
 
 cells), incubated
for 15 min at 4
 
 
 
C, and positively selected using MACS
 
®
 
 MS col-
umns according to manufacturer’s instructions (Miltenyi Biotec).
T cell subpopulations of CD4
 
 
 
CD25
 
 
 
 T cells were used imme-
diately after isolation. All the plate-bound anti-CD3 cultures re-
ceived 10
 
4
 
 irradiated PBMCs. In separate experiments, cells were
isolated using a MoFlo cell sorter after staining using FITC-con-
jugated anti-CD4 and Cy-Chrome–conjugated anti-CD25. The
purities of the populations obtained using these two methods of
cell isolation are shown in Fig. S1, available at http://www.jem.
org/cgi/content/full/jem.20040165/DC1.
 
Cytokine Detection.
 
For analysis of intracellular cytokine pro-
duction T cells were stimulated with either 5 
 
 
 
g/ml of soluble
anti-CD3/anti-CD28 or 1 
 
 
 
g/ml of plate-bound anti-CD3/irra-
diated PBMCs for 48 h. 2 
 
 
 
M monensin was added for the last
5 h. Staining of CD4 and CD25 surface expression was performed.
Cells were washed, fixed, permeabilized, and stained for detec-
tion of intracellular cytokines using PE-conjugated anti-IFN
 
 
 
,
TNF
 
 
 
, or IL-10. Alternatively, supernatants were collected, be-
fore the addition of monensin, and IL-2, IL-4, IL-5, IL-10,
IFN
 
 
 
, and TNF
 
 
 
 levels were measured by the cytometric bead
array kit (CBA kit; BD Biosciences), according to the manufac-
turer’s instructions.
 
Proliferation Assay. 
 
To assess proliferation of different CD4
 
 
 
subtypes, 10
 
5
 
 cells sorted of MACS purified T cells were incu-
bated in complete medium with 1 
 
 
 
g/ml of plate-bound anti-
CD3, 1 
 
 
 
g/ml of plate-bound anti-CD3, and 5 
 
 
 
g/ml of soluble
anti-CD28 or 5 
 
 
 
g/ml of soluble anti-CD3/anti-CD28 in 96-
well U-bottom plates (Nunc). After 5 d of culture, [
 
3
 
H]Tdr was
added for the remaining 8 h of culture. Proliferation was mea-
sured using a liquid scintillation counter.
 
Flow Cytometric Analysis. 
 
Immunofluorescence staining was
performed after washing the cells twice with PBS plus 0.5% hu-
man serum albumin. Cells were incubated for 20 min at 4
 
 
 
C with
each mAb (5 
 
 
 
g/ml, 10
 
5
 
 cells/test). After washing with cold
PBS/human serum albumin, the indirectly labeled cells were in-
cubated with FITC- and PE-conjugated second-step mAb for 20
min at 4
 
 
 
C, washed three times, and analyzed by flow cytometry
(FACScalibur™, CELLQuest™ software; Becton Dickinson).
 
Statistical Analysis. 
 
Analysis for statistically significant differ-
ences was performed with Student’s 
 
t
 
 test. p-values 
 
 
 
0.05 were
considered significant.
 
Online Supplemental Material. 
 
Fig. S1 shows the purity of the
populations isolated using either a MoFlo cell sorter or a MACS
 
®
 
column as analyzed by FACS
 
®
 
. The clinical details of the pa-
tients studied are included in Table S1. Online supplemental
material is available at http://www.jem.org/cgi/content/full/
jem.20040165/DC1.
 
Results
 
CD4
 
 
 
CD25
 
 
 
 T Cells Isolated from RA Patients Are Aner-
gic and Suppress the Proliferation of Effector T Cells. 
 
To test
the hypothesis that CD4
 
 
 
CD25
 
 
 
 regulatory T cells isolated
from active RA patients may be functionally defective com-
pared with those isolated from healthy individuals, or from
the same patients after anti-TNF
 
 
 
 treatment, CD4
 
 
 
CD25
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T cells were purified by MACS
 
®
 
 sorting (as described in
Materials and Methods) and cultured alone or mixed with
CD4
 
 
 
CD25
 
 
 
 T cells. Three different stimuli were used to
reveal any possible defect in the CD4
 
 
 
CD25
 
 
 
 T cell popu-
lation in the PB of patients with RA. The results in Fig. 1 A
show that CD4
 
 
 
CD25
 
 
 
 T cells isolated from active RA pa-
tients displayed an anergic phenotype and were able to in-
hibit the proliferation of effector CD4
 
 
 
CD25
 
 
 
 T cells in a
dose-dependent mode when different T cell receptor signal
strengths were used. CD4
 
 
 
CD25
 
 
 
 T cells isolated from ac-
tive RA patients were capable of suppressing the prolifera-
tion of responder T cells to a similar level as found in
healthy individuals or in the same group of patients 3 mo af-
ter anti-TNF
 
 
 
 treatment (unpublished data).
 
CD4
 
 
 
CD25
 
 
 
 Regulatory T Cells Isolated from RA Patients
Do Not Suppress Cytokines Produced by Effector T Cells.
 
As proinflammatory cytokines play an essential role in the
pathogenesis of RA, next we assessed whether CD4
 
 
 
CD25
 
 
 
 regulatory T cells, isolated before and after
anti-TNF
 
 
 
 treatment, were able to suppress proinflamma-
tory cytokine production by effector T cells. Similar to the
suppressive effects that regulatory T cells have on the pro-
liferation of effector T cells, the high levels of TNF
 
  and
IFN  synthesized by the responder CD4  T cells were
Figure 1. Regulatory T cells from the PB of patients with active RA can suppress proliferation but not proinflammatory cytokine production by effector
T cells and monocytes. (A) PB was collected from patients with RA; MACS®-sorted CD4 CD25  T cells and CD4 CD25  T cells were cultured either
alone or mixed at 1:3, 1:2, 1:1 ratio (105 cells/well) and stimulated with 1  g/ml of plate-bound anti-CD3, 1  g/ml of plate-bound anti-CD3/5  g/ml
of soluble anti-CD28, and 5  g/ml soluble anti-CD3/anti-CD28 for 48 h. Proliferation after 5 d was determined by 3[H]Tdr incorporation. Results are
expressed as mean   SEM of triplicate cultures. One out of five independent experiments is shown. (B) MACS®-sorted CD4 CD25  and CD4 CD25 
T cells isolated from 10 patients before and after anti-TNF  therapy (3 mo) with 5 patients responding to methotrexate therapy or 10 healthy controls
were cultured alone or mixed at a 1:1 ratio (105 cells/well) and stimulated with 5  g/ml of soluble anti-CD3/anti-CD28 for 48 h. Monocytes were stim-
ulated with 10 ng/ml LPS for 48 h. 2  M monensin was added for the last 5 h of culture. Staining of CD4 and CD25 surface expression was performed
and, subsequently, the cells were washed, permeabilized, and stained with PE-conjugated anti-TNF  or anti-IFN . (C) Cytokines from the supernatants
collected from the experiment (B) were measured by CBA. 1 out of 10 experiments is illustrated.Defective Regulatory T Cells in Rheumatoid Arthritis 280
suppressed after coculture with CD4 CD25  T cells de-
rived from healthy or anti-TNF –treated patients (Fig. 1
B). However, regulatory T cells isolated from patients with
active RA failed to inhibit the production of these cyto-
kines by CD4 CD25  effector T cells. Similarly, TNF 
production by monocytes, a key producer of this cytokine
in RA, was also markedly inhibited by CD4 CD25  T
cells isolated from healthy individuals and patients with RA
after treatment. No IL-10 production was detected in any
of the samples analyzed (unpublished data). The response of
CD4 CD25  T cells isolated from patients responding to
methotrexate treatment was included in this analysis. Al-
though CD4 CD25  T cells efficiently suppressed TNF 
produced by monocytes, the ability to inhibit cytokines
produced by effector T cells was less effective compared
with CD4 CD25  T cells isolated from anti-TNF –
treated patients (20–30% inhibition compared with 60–
70% inhibition after anti-TNF ). To complement the re-
sults obtained by intracellular staining, cytokine production
was also measured in the supernatants derived from the
aforementioned experiments by CBA. In keeping with the
results obtained from the intracellular staining, only regu-
latory T cells isolated from anti-TNF –treated patients
strongly suppressed TNF  and IFN  released by effector
CD4 CD25  T cells upon anti-CD3/CD28 stimulation in
vitro. A reduction in IL-2 production was detected in both
groups. Comparable results were obtained when plate-
bound anti-CD3 and irradiated PBMCs were used instead
of soluble stimuli (unpublished data).
CD4 CD25high T Cells from Active RA Patients Are Func-
tionally Defective.  The results described thus far are based
on the use of populations of CD4 CD25  T cells purified
with magnetic beads, containing mixtures of CD25high and
CD25low cells. It has been shown previously that amongst
CD4  T cells expressing CD25, only those expressing high
levels of CD25 display regulatory function (10). To dissect
which subset of CD4 CD25  T cells (high or low) was re-
sponsible for the suppressive effect on cytokines released by
the effector T cells, CD4  T cells were sorted according to
their CD25 expression (Fig. S1 A, available at http://
www.jem.org/cgi/content/full/jem.20040165/DC1). Re-
sults in Fig. 2 A demonstrate that the suppressive effect on
cytokine production resides in the CD4 CD25high T cell
fraction when isolated from anti-TNF –treated patients. In
contrast, the CD4 CD25high T cells from patients with ac-
tive RA were unable to suppress TNF  and IFN  pro-
duced by CD4 CD25  T cells. No differences were found
in TNF  or IFN  produced by CD4 CD25high T cells iso-
lated from patients before or after anti-TNF  treatment.
Cytokines were also measured in the culture supernatants
by CBA, and the results in Fig. 2 B reproduce the afore-
mentioned findings. In agreement with the suppression of
proliferation results shown in Fig. 1 A, regulatory T cells ir-
respective of their provenance strongly suppressed the pro-
duction of IL-2 released by autologous effector T cells. No
consistent changes in IL-5, IL-4, and IL-10 were found in
the different samples analyzed (unpublished data). Together,
Figure 2. The regulatory defect resides within the CD4 CD25high T
cell population. (A) The CD4 CD25 , CD4 CD25low, CD4 CD25high
population were FACS®-sorted (MoFlo) from an active RA patient before
treatment (white columns) and a responding RA patient (black columns)
receiving anti-TNF  therapy using the indicated gates is depicted in Fig. S1.
The CD4 CD25high and the CD4 CD25low T cells were cultured alone
or with CD4 CD25  responder T cells (5   104 cells/well) and stimu-
lated with 5  g/ml of soluble anti-CD3/anti-CD28 for 48 h. 2  M
monensin was added for the last 5 h of culture. Cells were stained to detect
intracellular TNF  and IFN  in a similar fashion to those in Fig. 1 B.
Mean   SEM of three patients before and after anti-TNF  therapy is
shown. (B) Cytokines from the supernatants collected from the experi-
ments from the three patients before and after anti-TNF  treatment (A)
were measured by CBA and shown separately in each of the panels.Ehrenstein et al. 281
these results demonstrate that regulatory T cells isolated
from patients with active RA are “compromised” at least in
terms of their ability to suppress proinflammatory cytokine
production by responder T cells as well as from monocytes.
Next, we investigated the possibility that effector T cells
are resistant to the suppressive effect exerted by the regu-
latory T cells in patients with RA. CD4 CD25  or
CD4 CD25high T cells from patients before therapy were
cultured with either CD4 CD25high T cells or with
CD4 CD25  T cells isolated 3 mo after therapy. The re-
sults in Fig. 3 show that CD4 CD25high T cells from active
RA patients were unable to suppress the production of cy-
tokines released by effector T cells isolated after anti-TNF 
treatment. In contrast, 3 mo after anti-TNF  therapy,
CD4 CD25high T cells regained their ability to inhibit
IFN  and TNF  released by autologous effector T cells
from active RA patients. The same conclusion could be
drawn whether the cultures were stimulated with soluble
anti-CD3/anti-CD28 (Fig. 3, top) or plate-bound anti-
CD3 (Fig. 3, bottom). Therefore, our data demonstrate
that CD4 CD25high T cells are functionally defective in
RA patients and the lack of suppression is not due to effec-
tor T cell resistance.
In the next experiment, we wished to establish whether
the recovery in function mediated by anti-TNF  therapy is
cell contact dependent and cytokine independent. In cocul-
ture experiments, freshly isolated CD4 CD25  T cells were
separated in transwell chambers from CD4 CD25high T
cells. Prevention of cell contact abolished their suppressive
capacity (Fig. 4 A). Next, we investigated whether addition
or neutralization of TNF  in vitro affects regulatory T cells.
The results in Fig. 4 B demonstrate that the addition of
TNF  to the coculture system did not alter the suppressive
function of regulatory T cells isolated after anti-TNF 
treatment. In vitro neutralization of TNF  (Infliximab) was
not sufficient to restore the defect in CD4 CD25high T cell–
mediated suppression (unpublished data).
Depletion of CD4 CD25  T Cells from PB Isolated from
Anti-TNF –treated Patients Results in an Increase in TNF 
Levels and in an Inhibition of IL-10 Production.  Next, we
evaluated how CD4 CD25  T cell depletion influences
Figure 3. CD4 CD25high T cells from
patients with active RA fail to suppress cy-
tokines produced by CD4 CD25  T cells
derived from the same patient either before
or after anti-TNF  therapy. CD4 CD25high
and CD4 CD25  T cells (5   104 cells/
well) isolated from patients with active RA
(n   3) or from patients responding to anti-
TNF  therapy (n     3) were mixed and
stimulated with 5  g/ml of soluble anti-
CD3/anti-CD28 (top) or with 1 mg/ml of
plate-bound anti-CD3 (bottom). Supernatants
were analyzed by CBA. The results indicate
the percentage of inhibition of the cytokine
production relative to the CD4 CD25  T
cells stimulated alone. One out of two experi-
ments is shown.
Figure 4. The inhibitory effect of CD4 CD25high T cells requires cell
contact and is not affected by the addition of TNF  in vitro. (A)
CD4 CD25high and responder T cells derived from patients responding to
anti-TNF  therapy were stimulated with 5 mg/ml of soluble anti-CD3/
anti-CD28 either with or without the use of a transwell membrane to
prevent cell contact. (top) 2  M monensin was added for the last 5 h of
culture, and cells were stained for detection of intracellular cytokine pro-
duction. (bottom) Cytokines from the supernatants collected from the
same experiment were measured by CBA. (B) CD4 CD25high and
CD4 CD25  T cells isolated from healthy as well as responding patients
were cultured 1:1 ratio, upon anti-CD3/anti-CD28 stimulation, in the
presence of different concentrations of TNF . The percentage of suppression
of cytokine production was calculated in each individual. One out of two
experiments is shown.Defective Regulatory T Cells in Rheumatoid Arthritis 282
the cytokine profile of PB before and after anti-TNF 
treatment. PB from patients with active RA synthesized
high levels of TNF , but no IL-10 (Fig. 5). After treat-
ment, a reduced amount of TNF  and an increased num-
ber of IL-10–secreting cells were detected in PB. After
depletion of CD4 CD25high T cells from PB derived from
patients with active RA, there was no change in the per-
centage of cells producing TNF  or IL-10, whereas a
fivefold increase in TNF  and a  10-fold reduction in
IL-10 production occurred when regulatory T cells were
depleted from anti-TNF –treated RA patients. Analysis
of PB from healthy individuals gave similar results to pa-
tients responding to anti-TNF  therapy. These results
provide additional evidence that regulatory T cells from
patients with active RA are ineffective in terms of sup-
pressing TNF  release and that this function is restored
after treatment.
CD4 CD25  Regulatory T Cells from Active RA Patients
Lack the Ability to Convey Suppressor Activity to Effector T
Cells: Restoration after Anti-TNF  Treatment.  The gener-
ation of newly formed regulatory T cells may be a further
mechanism by which regulatory T cells could control au-
toreactive T cells and the consequent inflammation. It has
been shown recently that regulatory T cells, isolated from
healthy individuals, convey a suppressive phenotype to
“conventional” activated T cells (19). To explore this pos-
sibility in patients with RA, we tested the capacity of regu-
latory T cells, isolated before and after treatment, to con-
vey a suppressive phenotype to CD4 CD25  T cells.
CD4 CD25  T cells were isolated as previously men-
tioned and cultured 1:1 with the CD4 CD25 T cell frac-
tion in the presence of soluble anti-CD3/anti-CD28. After
3 d, CD4 CD25  T cells were depleted, and the remain-
ing negative fraction (CD4 CD25 ) was cultured 1:1 with
freshly isolated autologous CD4 CD25  T cells for an ad-
ditional 5 d. In agreement with results reported from
Jonuleit et al. (19), the resulting CD4 CD25  T cell frac-
tion purified from healthy or anti-TNF –treated patients
suppressed the proliferation of freshly isolated autologous T
cells (Fig. 6). In contrast, similarly prepared CD4 CD25 
T cells from patients with active RA showed no suppres-
sive activity on freshly isolated T cells, suggesting that regu-
latory T cells from these patients are unable to imprint a
“suppressive” phenotype onto the CD4 CD25  T cells.
As an additional control, we also depleted CD4 CD25  T
cells (which should represent the newly activated T cells)
from the CD4 CD25  T cells cultured alone, and replated
with freshly isolated CD4 CD25  T cells. No suppressive
phenotype was acquired under these experimental condi-
tions (unpublished data), confirming that this phenomenon
is regulatory T cell dependent. These results demonstrate
that regulatory T cells isolated from patients with active
RA are unable to inhibit the production of proinflamma-
tory cytokines and to induce the differentiation of addi-
tional populations of suppressor cells.
Figure 5. Effect of depletion of CD4 CD25  T cells from PBMCs on
TNF  and IL-10 production from the same patient before and after treat-
ment. Total PBMCs or PBMCs depleted of CD25  cells (by MACS® sort-
ing) were stimulated with 5  g/ml of soluble anti-CD3/anti-CD28 for 48 h.
2  M monensin was added for the last 5 h of culture. Staining of CD4 and
CD25 surface expression was performed. Cells were permeabilized and
stained with PE-conjugated anti-TNF  or anti–IL-10. Results from three
patients before and after therapy and three healthy individuals are shown.
Figure 6. Only CD4 CD25  regulatory T cells derived from patients
treated with anti-TNF , but not from patients with active RA, convey a
suppressive phenotype to effector T cells. MACS®-sorted CD4 CD25 
T cells and CD4 CD25  T cells were cultured either alone or mixed at a
1:1 ratio (105 cells/well) and stimulated with 1  g/ml of soluble anti-
CD3 and 2  g/ml anti-CD28. After 5 d of culture, CD4 CD25  T cells
were depleted and the remaining CD4 CD25  T cells were replated 1:1
with freshly isolated autologous CD4 CD25  T cells in the presence of
anti-CD3 and anti-CD28 for an additional 3 d (third column). 3[H]Tdr
was added for the final 8 hof culture (expressed as mean   SEM of tripli-
cate cultures). Results from three patients before and after therapy and
three healthy individuals are shown.Ehrenstein et al. 283
The Frequency of CD4 CD25high T Cells Is Higher in Anti-
TNF –responding Patients Compared with the Same Patients
before Treatment. Finally, we monitored the numbers of
regulatory T cells in patients with RA, before and after
treatment (Table S1, available at http://www.jem.org/
cgi/content/full/jem.20040165/DC1). The expression of
CD25high/low on CD4  T cells was initially examined in
four responding and four nonresponding patients during
the first 3 mo of treatment using FACS® analysis. Although
the percentage of CD4 CD25high T cells increased over
time in those patients who responded to anti-TNF 
therapy, there was no change in the percentage of CD4 
CD25high T cells in the four nonresponding patients (Fig.
7 A). The percentage of this population continued to rise
in three out of the four responding patients 6 wk after
the first infusion of Infliximab and remained stable after 3
mo of treatment (unpublished data). The subsequent analy-
sis in a larger cohort of patients, including those responding
to methotrexate therapy, revealed that the percentage of
both CD4 CD25high/low T cells was significantly increased
in anti-TNF –responding patients compared with the lev-
els measured in those with active RA, methotrexate-
treated patients, and healthy controls (Fig. 7, B and C). Ac-
tive RA patients also showed an increased percentage of
CD4 CD25low T cells, which likely reflects increased acti-
vation of CD4  T cells, and does not represent any changes
in the regulatory T cell population, in accordance with our
(Fig. 2) and previously published data indicating that the
regulatory CD4  T subset is largely found within the
CD25high subset (10). The methotrexate-treated individuals
were matched to the responding anti-TNF –treated pa-
tients with respect to their response to treatment. Consis-
tent with previous results, no reduction in numbers of reg-
ulatory T cells was measured in patients with active RA
compared with healthy individuals (17), suggesting that nu-
merical deficiency is unlikely to be responsible for any
break in immune tolerance in RA, as has been suggested in
some mouse models of autoimmune disease (3, 4), and in
patients with type 1 diabetes mellitus (14). No differences
in CD4 CD25high/low expression were detected in patients
with RA who failed to respond to anti-TNF  therapy
compared with healthy controls. A significant correlation
between the CRP, a measure of rheumatoid disease activ-
ity, and the percentage of CD4 CD25high T cells (but not
CD4 CD25low) confirmed the relationship between a re-
sponse to anti-TNF  therapy and an expansion in this cell
population (Fig. 7 D). In agreement with previous papers,
there was no significant change in the absolute numbers of
CD4  T cells in PBMCs before treatment and 3 mo after
anti-TNF  treatment, indicating that the changes in per-
centages observed in CD4 CD25  T cells reflected alter-
ations in the absolute numbers of cells (20).
Discussion
The data presented here provide new insight into the bi-
ology of regulatory T cells within the context of a human
autoimmune disease. CD4 CD25high T cells isolated from
patients with active RA, although still anergic, show com-
promised function as demonstrated by their inability to
regulate proinflammatory cytokines released by effector T
cells and monocytes. After Infliximab treatment, regula-
tory T cell–mediated suppression was restored to the level
found in healthy individuals, whereas only a partial restora-
tion was seen in regulatory T cells isolated from patients re-
sponding to methotrexate. Although it is well documented
that Infliximab blocks both soluble and transmembrane
TNF , resulting in a strong inhibition of other proinflam-
matory cytokines, there is no unanimity about the effects of
methotrexate on cytokine production in RA (21, 22). If
proinflammatory cytokines are not efficiently suppressed in
methotrexate-treated patients, this could have a deleterious
effect on the function of regulatory T cells, thus explaining
the different level of regulatory T cell–mediated inhibition
in patients treated with these two therapies.
It is unclear why regulatory T cells isolated from RA pa-
tients are unable to suppress lymphocyte and monocyte cy-
tokine production. One possibility is that the presence of
TNF  as well as other proinflammatory cytokines may
hinder the ability of regulatory T cells to prevent autoim-
mune disease. In a recent paper that examined the role of
this cytokine with respect to regulatory T cells, TNF  im-
paired the ability of regulatory T cells to suppress disease in
Figure 7. Increase in CD4 CD25high T cells in the PB of RA patients
responding to anti-TNF  therapy. (A) The percentage of CD4  T cells
expressing CD25high was followed in four anti-TNF  responder (dashed
line) and four nonresponder (solid line) patients with RA before and after
treatment. (B) Analysis of larger group of patients treated with anti-TNF 
(n   27), methotrexate alone (n   6), and healthy controls (n   8).
CD4 CD25high and (C) CD4 CD25low T cells (as defined in Fig. S1 A).
(D) Scatter plot showing a significant correlation between the C reactive
protein and the percentage of CD4 CD25high T cells before and after
treatment (P   0.001, r2   0.5278).Defective Regulatory T Cells in Rheumatoid Arthritis 284
the NOD mouse model of diabetes (4). These authors sug-
gested that endogenous levels of TNF  might act centrally
in the thymus to mediate these effects on regulatory T cells.
Pertinent to their hypothesis is the recent observation that
CD4 CD25  T cells derived from the thymus of healthy
donors have an increased expression of TNFRII compared
with CD4 CD25  T cells (12), which might result in an
increased susceptibility of regulatory T cells to the actions
of TNF . However, our in vitro data do not lend support
to a direct effect of TNF  on regulatory T cells because,
after exposure to a gradient of TNF  concentration alone,
regulatory T cells were still viable and functionally active.
These results indicate that more complex mechanisms are
likely to operate in vivo. That regulatory T cells isolated
from patients affected by chronic inflammatory disorders
show altered function is not only peculiar to RA. Indeed, it
has been reported recently that regulatory T cells isolated
from the PB of patients with multiple sclerosis are func-
tionally defective in terms of their ability to suppress prolif-
eration and cytokines production by activated T cells (23).
This finding, together with our data, might shed some light
on the role that regulatory T cells play in controlling the
maintenance of peripheral tolerance and in the prevention
of human autoimmunity.
It has been speculated previously that the spreading of
suppression from CD4 CD25  T cells to responder T cells
is an important mechanism by which regulatory T cells ex-
ert their effect in the maintenance of peripheral tolerance
(19). This is an attractive explanation for how such small
numbers of cells could prevent autoimmune disease. Our
in vitro data suggest that, unlike regulatory T cells from
healthy individuals, those derived from active RA patients
cannot convey a suppressive phenotype to activated T cells.
To our knowledge, this is the first time that this phenome-
non has been shown to be impaired in an autoimmune dis-
ease. This defect could have a significant impact on the
regulation of RA pathology because it is likely that the
generation of newly formed (and fully functional) suppres-
sor T cells is critical to control autoimmunity.
In searching for the mechanism by which these regula-
tory T cells act, we found that the suppression of cytokine
production by regulatory T cells after treatment was con-
tact dependent, and soluble factor independent as neutral-
ization of IL-10 and TGF  did not alter their suppressive
function (unpublished data). However, depletion of CD4 
CD25  T cells from treated PB led to a reduction in the
number of IL-10–secreting cells. This suggests that the pro-
duction of IL-10 may be dependent on the presence of
regulatory T cells, but that its release is by another popula-
tion such as a subset of suppressor cells that do not express
CD25. It has been suggested that CD4 CD25  T cells
may actively promote the differentiation of Tr1 cells that
mediate their suppression through production of IL-10
(24). As IL-10 is widely known for its antiinflammatory
properties, it is tantalizing to hypothesize that the increase
in this cytokine, previously reported in anti-TNF –treated
patients (20, 25), is orchestrated by regulatory T cells whose
function has been restored. Interestingly, we were unable
to detect IL-10 in any of the T cell populations analyzed,
suggesting that the production of IL-10 depends on the in-
teraction of a variety of cell types (and/or their soluble
products) present in whole PBMCs.
The other major finding described in our paper is the in-
creased regulatory T cell number in RA patients treated
with anti-TNF , which significantly correlated with a re-
duction in CRP value. It is tempting to speculate that the
increase in regulatory T cells in responding patients is im-
portant in the amelioration of disease and may help to dif-
ferentiate between responder and nonresponder patients
because the changes occur within 6 wk of initiation of
therapy. It is conceivable that TNF  has a direct effect on
regulatory T cell viability, such as the induction of apopto-
sis (26), which would explain the increased number of reg-
ulatory T cells after TNF  neutralization. As aforemen-
tioned, our in vitro data do not support this hypothesis.
Moreover, we found no reduction in regulatory T cell
numbers in patients with active RA compared with healthy
donors, suggesting that neither apoptosis, nor any other di-
rect effect on regulatory T cell numbers, are the primary
mechanisms by which TNF  is acting. The lack of differ-
ence in CD25high regulatory T cell numbers found in active
patients, compared with healthy individuals, needs more
careful study, as the CD25high regulatory T cells derived
from active RA could be “contaminated” by recently acti-
vated CD4  T cells, which would mask the total number
of regulatory T cells. Indeed, human CD4 CD25  T cells
are not a homogenous population and contain nonsuppres-
sive fractions (10, 27). Of equal importance to the issues al-
ready raised is the possibility that an increase in regulatory
T cells may have deleterious consequences, in particular an
increased susceptibility to infections, which is a major issue
in patients receiving anti-TNF  therapy (28).
Further studies are required to elucidate the mechanisms
that underlie these observations in patients with RA, and to
relate the clinical and immunological responses in patients
receiving anti-TNF  therapy. Restoration of the function
of regulatory T cells or transfer of fully competent regula-
tory T cells could be a useful therapeutic tool in the treat-
ment of RA (29).
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